Isoliquiritigenin

Isoliquiritigenin (2',4',4-trihydroxychalcone, commonly abbreviated ISL, ILG, or ILN) is a chalcone-class flavonoid found chiefly in the roots of licorice species (Glycyrrhiza glabra, G. uralensis, G. inflata) and, in smaller amounts, in shallot, bean sprouts, and other plants. Structurally it is the open-chain (ring-opened) counterpart of the flavanone liquiritigenin, and its conjugated enone gives it a characteristic yellow color and a reactive Michael-acceptor chemistry that underlies much of its biology. Across preclinical work it has been described as antioxidant, anti-inflammatory, antiplatelet, anti-diabetic, and antitumor, and reviews frame it as a multi-target natural compound rather than a single-receptor drug ^[1].

One of the most studied properties is inhibition of aromatase (CYP19A1), the enzyme that converts androgens to estrogens. In a dietary-administration study, isoliquiritigenin inhibited recombinant aromatase and slowed the growth of aromatase-overexpressing MCF-7 breast cancer cells and their xenografts in mice without reducing body weight ^[2]. Because of this and its effects on estrogen-receptor signaling, angiogenesis, and proliferation, it is frequently discussed as a candidate in hormone-related breast cancer; reviews stress that these findings are promising but remain confined to cell and animal models and require clinical validation before any therapeutic claim ^[3].

Its anti-inflammatory and cytoprotective actions have been mapped to a recurring molecular pattern: activation of the Nrf2/ARE antioxidant program alongside suppression of NF-kB and the NLRP3 inflammasome. In macrophages and a mouse model of LPS-induced acute lung injury, isoliquiritigenin induced AMPK/Nrf2 signaling and reduced reactive oxygen species while blunting NLRP3 and NF-kB, easing pulmonary edema and injury ^[4]. A similar Nrf2-dependent mechanism reduced NLRP3-driven damage after experimental intracerebral hemorrhage in rats, with the benefit lost when Nrf2 was silenced ^[5], and the same pathways were implicated in protection against cigarette-smoke-induced COPD-like lung inflammation ^[6]. In cancer models it has additionally been shown to raise ROS and inhibit the Jak2/STAT3 pathway, driving apoptosis in renal carcinoma cells ^[7].

Pharmacokinetics are a major practical limitation. Isoliquiritigenin is extensively metabolized by phase II UDP-glucuronosyltransferases to glucuronide conjugates, which contributes to low systemic exposure after oral intake ^[8]; combined with poor aqueous solubility, this gives it modest oral bioavailability and has motivated formulation work (nanoparticles, complexes) in the lab. Human pharmacokinetic and efficacy data are effectively absent, so the animal doses used to produce these effects do not translate into a validated human regimen. Overall the compound has a broad and internally consistent preclinical profile, but it should be read as an early-stage research molecule rather than a proven supplement.

purified isoliquiritigenin has a generally clean preclinical tolerability record, but there is no meaningful human safety data, so caution is the default. two specific flags: it's an aromatase inhibitor and phytoestrogen-active, so it's not appropriate to casually combine with hormone therapy, fertility treatment, or in hormone-sensitive conditions, and it should be avoided in pregnancy. it also has antiplatelet activity in the lab, which matters if you're on blood thinners or heading into surgery. importantly, if you're getting ISL through a whole-licorice extract, that extract can contain glycyrrhizin, which raises blood pressure and lowers potassium (pseudoaldosteronism); that risk belongs to licorice, not to purified ISL, but most people encounter the two together. talk to a clinician before using it alongside any medication.

Isoliquiritigenin has been consumed indirectly for millennia as a constituent of licorice root, long used in traditional Chinese and other herbal medicine. It was later isolated and characterized as the chalcone (ring-opened) counterpart of liquiritigenin, and from the 1990s onward became a focus of chemoprevention and anti-inflammatory pharmacology research.

Within nutraceutical and research circles it has a reputation as a promising multi-target licorice flavonoid; antioxidant, anti-inflammatory, and aromatase-inhibiting; but one whose real-world use is limited by poor oral bioavailability and an almost complete lack of human clinical data.